A month has gone by since the last earnings report for Ingevity Corporation (NGVT). Shares have added about 2.4% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Ingevity Corporation due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at the most recent earnings report in order to get a better handle on the important drivers.

Ingevity’s Q2 Earnings & Revenues Beat Estimates

Ingevity recorded a profit (attributable to stockholders) of $46.7 million or $1.10 per share in second-quarter 2018, surging roughly 45% from $32.1 million or 76 cents a year ago.

Barring one-time items, earnings came in at $1.12 per share in the quarter, surpassing the Zacks Consensus Estimate of 99 cents.

The company’s revenues rose roughly 19% year over year to $308.6 million in the quarter, squeaking past the Zacks Consensus Estimate of $308.2 million.

Adjusted EBITDA climbed roughly 33% year over year to $89.4 million in the quarter.

The company gained from strong organic growth, contributions of Georgia-Pacific pine chemicals acquisition, excellent commercial and operational execution and strong productivity.

Segment Review

Revenues from the Performance Chemicals division jumped around 24% year over year to $212.5 million in the quarter. Revenues were driven by sales growth in oilfield industry on the back of higher U.S. drilling and production, along with the strong adoption of the company’s pavement technologies. The buyout of Georgia-Pacific pine chemicals business also supported the growth.   

Revenues from the Performance Materials unit went up around 7% to $96.1 million. The growth was supported by strong volumes of the company’s solutions geared to meet the U.S. EPA Tier 3 and California LEV III emission regulations.

Balance Sheet

Ingevity ended the quarter with cash and cash equivalents of $83 million, a more than two-fold year over year increase. Long-term debt was $729.5 million, up around 57%.


Ingevity remains optimistic about 2018 as it is witnessing the benefits of improving market conditions for its basic materials and high-value added technologies. The company increased the mid-point and narrowed the range for its 2018 guidance for adjusted EBITDA to $302-$314 million from $293-$307 million. The company backed its sales guidance of between $1.10 billion and $1.13 billion for the year.

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed a downward trend in fresh estimates.

VGM Scores

At this time, Ingevity Corporation has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren’t focused on one strategy, this score is the one you should be interested in.

Our style scores indicate that the stock is more suitable for growth investors than momentum investors.


Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Ingevity Corporation has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ingevity Corporation (NGVT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research